A new trading day began on Monday, with Lyell Immunopharma Inc (NASDAQ: LYEL) stock price up 0.97% from the previous day of trading, before settling in for the closing price of $0.93. LYEL’s price has ranged from $0.87 to $3.26 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 428.28% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 10.22%. With a float of $114.05 million, this company’s outstanding shares have now reached $253.96 million.
In an organization with 224 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -37096.3%, operating margin of -422788.89%, and the pretax margin is -389368.52%.
Lyell Immunopharma Inc (LYEL) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Lyell Immunopharma Inc is 55.45%, while institutional ownership is 26.33%.
Lyell Immunopharma Inc (LYEL) Latest Financial update
In its latest quarterly report, released on 6/30/2024, the company reported earnings of -0.2 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.22 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 10.22% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -7.90% during the next five years compared to -15.28% drop over the previous five years of trading.
Lyell Immunopharma Inc (NASDAQ: LYEL) Trading Performance Indicators
Here are Lyell Immunopharma Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 16.19. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4792.32.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.83, a number that is poised to hit -0.20 in the next quarter and is forecasted to reach -0.88 in one year’s time.
Technical Analysis of Lyell Immunopharma Inc (LYEL)
Let’s dig in a bit further. During the last 5-days, its volume was 4.33 million. That was better than the volume of 0.97 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 11.82%. Additionally, its Average True Range was 0.11.
During the past 100 days, Lyell Immunopharma Inc’s (LYEL) raw stochastic average was set at 4.18%, which indicates a significant decrease from 18.52% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 90.42% in the past 14 days, which was lower than the 115.64% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2879, while its 200-day Moving Average is $1.9040. However, in the short run, Lyell Immunopharma Inc’s stock first resistance to watch stands at $1.0240. Second resistance stands at $1.1119. The third major resistance level sits at $1.1939. If the price goes on to break the first support level at $0.8541, it is likely to go to the next support level at $0.7721. The third support level lies at $0.6842 if the price breaches the second support level.
Lyell Immunopharma Inc (NASDAQ: LYEL) Key Stats
With a market capitalization of 239.62 million, the company has a total of 254,939K Shares Outstanding. Currently, annual sales are 130 K while annual income is -234,630 K. The company’s previous quarter sales were 10 K while its latest quarter income was -45,810 K.
